Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study)

European Journal of Human Genetics

Volumn 17, Issue 2, 2009, Pages 250-257

  Roten, Linda T ^a   Johnson, Matthew P ^b   Forsmo, Siri ^a   Fitzpatrick, Elizabeth ^c   Dyer, Thomas D ^b   Brennecke, Shaun P ^c   Blangero, John ^b   Moses, Eric K ^b   Austgulen, Rigmor ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2A; DNA; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; CHROMOSOME 2Q; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; ICELAND; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEW ZEALAND; NORWAY; PATHOGENESIS; PEDIGREE; POPULATION BASED CASE CONTROL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVIN RECEPTORS, TYPE II; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY;

EID: 58349118696     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.158     Document Type: Article

References (52)

1. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R: Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990; 163: 460-465.
2. Taylor D: The epidemiology of hypertension during pregnancy. Amsterdam: Elsevier, 1988.
3. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G: Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol 1990; 97: 762-769.
4. Moses EK, Fitzpatrick E, Freed KA et al: Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Hum Reprod 2006; 12: 505-512.
5. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S: Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256-260.
6. Chesley LC, Cooper DW: Genetics oP hypertension in pregnancy: possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 1986; 93: 898-908.
7. Cooper DW, Hill JA, Chesley LC, Bryans CI: Genetic control of susceptibility to eclampsia and miscarriage. Br J Obstet Gynaecol 1988; 95: 644-653.
8. Esplin MS, Fausett MB, Fraser A et al: Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344: 867-872.
9. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM: Fetal and maternal contributions to risk of preeclampsia: Population based study. BMJ 1998; 316: 1343-1347.
10. Arngrimsson R, Sigurard ttir S, Frigge ML et al: A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8: 1799-1805.
11. Harrison GA, Humphrey KE, Jones N et al: A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet 1997; 60: 1158-1167.
12. Lachmeijer AM, Arngrimsson R, Bastiaans EJ et al: A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9: 758-764.
13. Moses EK, Lade JA, Guo G et al: A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000; 67: 1581-1585.
14. Laivuori H, Lahermo P, Ollikainen V et al: Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003; 72: 168-177.
15. Caniggia I, Lye SJ, Cross JC: Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology 1997; 138 3976-3986.
16. Jones RL, Salamonsen LA, Findlay JK: Activin A promotes human endometrial stromal cell decidualization in vitro. J Clin Endocrinol Metab 2002; 87: 4001-4004.
17. Gribi R, Tanaka T, Harper-Summers R, Yu J: Expression of activin A in inflammatory arthropathies. Mol Cell Endocrinol 2001; 180: 163-167.
18. HubneA G, Brauchle M, Gregor M, Werner S: Activin A: a novel player and inflammatory marker in inflammatory bowel disease? Lab Invest 1997; 77: 311-318.
19. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 2001; 180: 155-162.
20. Engelse MA, Neele JM, van Achterberg TA et al: Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 1999; 85: 931-939.
21. Kozaki K, Akishita M, Eto M et al: Role of activin-A and follistatin in foam cell formation of THP-1 macrophages. Arterioscler Thromb Vasc Biol 1997; 17: 2389-2394.
22. Holmen J, Kjelsaas M, Krüger Ø et al: Attitudes to genetic epidemiology-illustrated by questions for re-consent to 61 426 participants at HUNT. Norsk Epidemiologi (Nor J Epidemiol) 2004; 14: 27-31.
23. Holmen J, Midthjell K, Krüger Ø et al: The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003; 13: 19-32.
24. Moses EK, Johnson MP, Tommerdal L et al: Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol 2008; 198: 336.e1-336.e5.
25. Masuda J, Takayama E, Satoh A et al: Levels of annexin IV and V in the plasma of pregnant and postpartum women. Thromb Haemost 2004; 91: 1129-1136.
26. Jaleel MA, Tsai AC, Sarkar S, Freedman PV, Rubin LP: Stromal cell-derived factor-1 (SDF-1) signalling regulates human placental trophoblast cell survival. Mol Hum Reprod 2004; 10: 901-909.
27. Manuelpillai U, Ligam P, Smythe G, Wallace EM, Hirst J, Walker DW: Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: Up-regulation by inflammatory stimuli and with clinical infection. Am J Obstet Gynecol 2005; 192: 280-288.
28. Hernandez PA, Gorlin RJ, Lukens JN et al: Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34: 70-74.
29. Almasy L, Blangero J: Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-1211.
30. Boerwinkle E, Chakraborty R, Sing CF: The use of measured genotype information in the analysis of quantitative phenotypes in man. I. Models and analytical methods. Ann Hum Genet 1986; 50: 181-194.
31. Li J, Ji L: Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221-227.
32. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284.
33. Blangero J, Goring HH, Kent Jr JW et al: Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol 2005; 77: 541-559.
34. Cocolakis E, Lemay S, Ali S, Lebrun JJ: The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001; 276: 18430-18436.
35. Zhang Z, Zhao Y, Batres Y, Lin MF, Ying SY: Regulation of growth and prostatic marker expression by activin A in an androgensensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 1997; 234: 362-365.
36. Donaldson CJ, Mathews LS, Vale WW: Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Commun 1992; 184: 310-316.
37. Mathews LS, Vale WW: Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991; 65: 973-982.
38. Hilden K, Tuuri T, Eramaa M, Ritvos O: Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor.Blood 1994; 83 2163-2170.
39. Schneider-Kolsky ME, Manuelpillai U, Waldron K, Dole A, Wallace EM: The distribution of activin and activin receptors in gestational tissues across human pregnancy and during labour. Placenta 2002; 23: 294-302.
40. Jones RL, Findlay JK, Salamonsen LA: The role of activins during decidualisation of human endometrium. Aust N Z J Obstet Gynaecol 2006; 46: 245-249.
41. Petraglia F, Vaughan J, Vale W: Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc Natl Acad Sci USA 1989; 86: 5114-5117.
42. Petraglia F, Anceschi MM, Calza L et al: Inhibin and activin in human fetal membranes: Evidence for a local effect on prostaglandin release. J Clin Endocrinol Metab 1993; 77: 542-548.
43. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW: Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45-55.
44. D'Antona D, Reis FM, Benedetto C et al: Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol 2000; 165: 157-162.
45. Laivuori H, Kaaja R, Turpeinen U, Stenman UH, Ylikorkala O: Serum activin A and inhibin A elevated in pre-eclampsia: No relation to insulin sensitivity. Br J Obstet Gynaecol 1999; 106: 1298-1303.
46. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL: Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997; 349: 1285-1288.
47. Petraglia F, Aguzzoli L, Gallinelli A et al: Hypertension in pregnancy: Changes in activin A maternal serum concentration. Placenta 1995; 16: 447-454.
48. Silver HM, Lambert-Messerlian GM, Star JA, Hogan J, Canick JA: Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999; 180: 1131-1137.
49. Petraglia F, Sawchenko P, Lim AT, Rivier J, Vale W: Localization, secretion, and action of inhibin in human placenta. Science 1987; 237: 187-189.
50. Smith C, Yndestad A, Halvorsen B et al: Potential antiinflammatory role of activin A in acute coronary syndromes. J Am Coll Cardiol 2004; 44: 369-375.
51. Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. Bmj 2007; 335: 974.
52. Dhar SK, Delmolino L, Dutta A: Architecture of the human origin recognition complex. J Biol Chem 2001; 276: 29067-29071.